Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

OSB H1 profits fall, maintains interim dividend

(Sharecast News) - Mortgage lender OSB Group said on Wednesday that profits had fallen in the six months ended 30 June, with rising funding costs and a competitive mortgage market weighing on profitability. Statutory pre-tax profits dropped 31% to £226.7m, hit by a 59% surge in impairment charges to £54.6m, while underlying pre-tax profits fell 25% to £260.6m, and operating income slipped 3% to £398.6m.

Loan book growth remained solid, up 6% to £24.4bn, but the group's cost-to-income ratio rose to 27%, compared with 24% a year earlier, and net interest margin narrowed to 2.56%, down from 2.78%, reflecting elevated savings rates and a shift in product mix. However, OSB maintained its interim dividend at 11.7p per share.

Looking forward, OSB expects margins to stabilise in the second half, but warned of ongoing uncertainty around arrears and customer behaviour. It also confirmed the launch of a £30m share buyback programme, citing strong capital generation and a resilient balance sheet.

Chief executive Andy Golding said: "The group's results for the first half of 2025 demonstrate resilient financial performance in line with management expectations in addition to strategic progress as we work our way through the two-year transition period.

"Given the performance in the first half of the year, today we reiterate our 2025 guidance of low single-digit net loan book growth, NIM of circa 225bps, circa £270m of administrative expenses and a low teens RoTE."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.